Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00294866 · ClinicalTrials.gov registry record · Phase 4
Effect of Paricalcitol on Markers of Inflammation in Hemodialysis Patients
A Phase 4 study, sponsored by Fresenius Medical Care North America.
- Completed
- Registry status
- Phase 4
- Development phase
- 64
- Enrollment target
NCT00294866 is a Phase 4 study that has completed, run by Fresenius Medical Care North America. The registered enrollment target is 64 participants.
The verdict
NCT00294866, a Phase 4 study, has completed, sponsored by Fresenius Medical Care North America.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 64 participants
- Enrollment target
Study Summary
Studies have shown that patients with ESRD on hemodialysis have high levels of inflammatory markers which may contribute to the high rates of cardiovascular disease and mortality seen in these patients. Vitamin D use in dialysis patients has been shown to have a survival benefit, with paricalcitol at advantage over calcitriol. Since there is some evidence for involvement of the vitamin D receptor in inflammation, this study is designed to look for an effect of paricalcitol on markers of inflammation in hemodialysis patients.
Interventions
- DRUG Paricalcitol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2006-03 |
| Est. Completion | 2008-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00294866
The ClinicalTrials.gov registry entry for NCT00294866 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fresenius Medical Care North America, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Paricalcitol is the first listed.
NCT00294866 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00294866 about?
NCT00294866 is a clinical study titled "Effect of Paricalcitol on Markers of Inflammation in Hemodialysis Patients". Studies have shown that patients with ESRD on hemodialysis have high levels of inflammatory markers which may contribute to the high rates of cardiovascular disease and mortality seen in these patients. Vitamin D use in dialysis patients has been shown to have a survival benefit, with paricalcitol a...
What is the current status of trial NCT00294866?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 64 participants. The study started on 2006-03. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00294866?
The interventions under investigation include: Paricalcitol (DRUG).
Who is sponsoring clinical trial NCT00294866?
This trial is sponsored by Fresenius Medical Care North America, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.